Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Receptor Tyrosine Kinase Gene Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07699328
What this trial is testing

VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

Who this might be right for
EGFR-Mutant Non-Small Cell Lung Cancer
Voronoi, Inc 315
Testing effectiveness (Phase 2)Study completedNCT01752920
What this trial is testing

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Who this might be right for
Solid Tumor
Basilea Pharmaceutica 119
Not applicableAvailableNCT03620318
What this trial is testing

Individual Patient Compassionate Use of Crenolanib

Who this might be right for
FLT3-ITD MutationFLT3/TKD MutationPDGFR-Alpha D842V+1 more
Arog Pharmaceuticals, Inc.
Large-scale testing (Phase 3)UnknownNCT03727867
What this trial is testing

Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer

Who this might be right for
Advanced Non-small Cell Lung Cancer
Haihua Yang 300
Not applicableStudy completedNCT02418234
What this trial is testing

T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

Who this might be right for
Non-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic
First People's Hospital of Hangzhou 314
Testing effectiveness (Phase 2)Ended earlyNCT02500927
What this trial is testing

ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Who this might be right for
EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
Astellas Pharma Inc 31
Early research (Phase 1)Active Not RecruitingNCT02503722
What this trial is testing

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage III Lung Non-Small Cell Cancer AJCC v7+3 more
National Cancer Institute (NCI) 36
Large-scale testing (Phase 3)Study completedNCT02151981
What this trial is testing

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Anticancer Treatment
AstraZeneca 421
Early research (Phase 1)Study completedNCT03452150
What this trial is testing

D-0316 First Time in Patients Ascending Dose Study

Who this might be right for
Advanced Non Small Cell Lung Cancer
InventisBio Co., Ltd 84
Not applicableStudy completedNCT01167972
What this trial is testing

Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 2,000
Testing effectiveness (Phase 2)Study completedNCT01250119
What this trial is testing

Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 688
Testing effectiveness (Phase 2)UnknownNCT02274337
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 100
Testing effectiveness (Phase 2)Study completedNCT02442349
What this trial is testing

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 171
Large-scale testing (Phase 3)Looking for participantsNCT05770037
What this trial is testing

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

Who this might be right for
Haematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+8 more
Cancer Research UK 30
Testing effectiveness (Phase 2)Study completedNCT01833572
What this trial is testing

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Who this might be right for
Non-small-cell Lung Cancer
Fudan University 36
Early research (Phase 1)Study completedNCT01999985
What this trial is testing

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Lung CancerNon-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute 25
Testing effectiveness (Phase 2)UnknownNCT03050437
What this trial is testing

A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Samsung Medical Center 96
Testing effectiveness (Phase 2)UnknownNCT04179656
What this trial is testing

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Who this might be right for
Solid TumorHER2 Gene MutationHER-2 Gene Amplification+1 more
Tianjin Medical University Second Hospital 100
Testing effectiveness (Phase 2)Study completedNCT06083662
What this trial is testing

Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers

Who this might be right for
Metastatic CancerHER2 Gene Mutation
Korea University Guro Hospital 42
Testing effectiveness (Phase 2)Study completedNCT01573702
What this trial is testing

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

Who this might be right for
Non Small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center 32
Next Page